CS
NTLA icon

Credit Suisse’s Intellia Therapeutics NTLA Stock Holding History

Credit Suisse’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,500
Closed -$567K – 4497
2021
Q2 		$567K Buy
+3,500
New +$273K ﹤0.01% 3765

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse's NTLA Position: Q1 2024 in Review

Credit Suisse increased its Intellia Therapeutics (NTLA) stake by 0.24% in Q1 2024, buying an estimated $8.8K and bringing the position to 134,497 shares worth $3.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1468.

Credit Suisse first reported a position in NTLA in Q3 2016 and has held it in 29 quarters since. The position peaked at $15.9M in Q2 2021. 285 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

  • Credit Suisse held 134,497 shares of Intellia Therapeutics worth $3.7M as of Q1 2024.
  • Credit Suisse bought 317 Intellia Therapeutics shares in Q1 2024, an estimated $8.8K.
  • Intellia Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1468 holding.
  • Credit Suisse first reported a position in Intellia Therapeutics in Q3 2016 and has held it in 29 quarters since.
  • Credit Suisse's Intellia Therapeutics position peaked at $15.9M in Q2 2021.
  • 285 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.